{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:36Z","timestamp":1793381016668,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clim.2021.108707","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T02:01:49Z","timestamp":1614564109000},"page":"108707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":195,"special_numbering":"C","title":["The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives"],"prefix":"10.1016","volume":"226","author":[{"given":"Jamal","family":"Majidpoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keywan","family":"Mortezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2021.108707_bb0005","article-title":"Immune escape: a critical hallmark in solid tumors","volume":"118110","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0010","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","article-title":"PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients","volume":"12","author":"Concha-Benavente","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2021.108707_bb0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0020","series-title":"Pembrolizumab in Patients with Non-small-Cell Lung Cancer of Performance Status 2 (PePS2): A Single Arm, Phase 2 Trial","author":"Middleton","year":"2020"},{"key":"10.1016\/j.clim.2021.108707_bb0025","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0040","article-title":"Immune system in cancer radiotherapy: resistance mechanisms and therapy perspectives","volume":"103180","author":"Mortezaee","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.clim.2021.108707_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22708","article-title":"Enriched cancer stem cells, dense stroma, and cold immunity: interrelated events in pancreatic cancer","author":"Mortezaee","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.clim.2021.108707_bb0050","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2018-0070","article-title":"Avelumab (anti-PD-L1) in platinum-resistant\/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design","volume":"14","author":"Pujade-Lauraine","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-017-0509-1","article-title":"Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer","volume":"36","author":"Shindo","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/cancers13030405","article-title":"Understanding and targeting natural killer cell-cancer-associated fibroblast interactions in pancreatic ductal adenocarcinoma","volume":"13","author":"Malchiodi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clim.2021.108707_bb0065","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jgh.15265","article-title":"Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma","volume":"36","author":"Lee","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2021.108707_bb0070","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.3390\/ijms15034104","article-title":"Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma","volume":"15","author":"Karakhanova","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0075","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3389\/fimmu.2019.01832","volume":"10","author":"Bassani-Sternberg","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108707_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-020-01447-w","article-title":"Steps in metastasis: an updated review","volume":"38","author":"Majidpoor","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molimm.2017.10.003","article-title":"Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer","volume":"92","author":"Liang","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.clim.2021.108707_bb0095","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0100","doi-asserted-by":"crossref","first-page":"109488","DOI":"10.1016\/j.cellsig.2019.109488","article-title":"CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration","volume":"66","author":"Nguyen","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.clim.2021.108707_bb0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12652-1","article-title":"Interval breast cancer is associated with other types of tumors","volume":"10","author":"Grassmann","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2021.108707_bb0115","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41388-020-01391-z","article-title":"Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow","volume":"39","author":"Buschhaus","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.clim.2021.108707_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820906811","article-title":"Laparoscopic surgery versus open surgery for colorectal cancer: impacts on natural killer cells","volume":"27","author":"Shi","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.clim.2021.108707_bb0125","first-page":"105","article-title":"Enhancing global access to cancer medicines","volume":"70","author":"Cortes","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clim.2021.108707_bb0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jcyt.2017.09.009","article-title":"Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma","volume":"20","author":"Li","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clim.2021.108707_bb0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"On behalf of the IMblaze370 investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells","volume":"5","author":"Lu","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2021.108707_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2021.108707_bb0160","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clim.2021.108707_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014290","article-title":"Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)","volume":"98","author":"Hoogstad-van Evert","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.clim.2021.108707_bb0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2016.04.002","article-title":"The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: a systematic review","volume":"142","author":"Zhu","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0180","series-title":"Pembrolizumab in Patients (Pts) with PD-L1\u2013Positive (PD-L1+) Advanced Ovarian Cancer: Updated Analysis of KEYNOTE-028","author":"Varga","year":"2017"},{"key":"10.1016\/j.clim.2021.108707_bb0185","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1172\/JCI99397","article-title":"Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming","volume":"128","author":"Mishra","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2021.108707_bb0190","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.clim.2021.108707_bb0195","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1634\/theoncologist.2018-0652","article-title":"Modulation of Premetastatic niche by the vascular endothelial growth factor receptor tyrosine kinase inhibitor Pazopanib in localized high-risk prostate Cancer followed by radical prostatectomy: a phase II randomized trial","volume":"23","author":"Maughan","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clim.2021.108707_bb0200","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2021.108707_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07511-4","article-title":"NSD2 is a conserved driver of metastatic prostate cancer progression","volume":"9","author":"Aytes","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2021.108707_bb0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-018-0409-8","article-title":"Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer","volume":"6","author":"Redman","year":"2018","journal-title":"J. Immunotherapy Cancer"},{"key":"10.1016\/j.clim.2021.108707_bb0215","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3389\/fonc.2020.517637","article-title":"The landscape of immune cells infiltrating in prostate cancer","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0220","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0225","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0230","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0235","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fphar.2019.00139","article-title":"The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clim.2021.108707_bb0240","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fimmu.2019.01206","article-title":"The reversal of immune exclusion mediated by tadalafil and an anti-tumor vaccine also induces PDL1 upregulation in recurrent head and neck squamous cell carcinoma: interim analysis of a phase I clinical trial","volume":"10","author":"Weed","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108707_bb0245","doi-asserted-by":"crossref","first-page":"117145","DOI":"10.1016\/j.lfs.2019.117145","article-title":"Hypoxia induces core-to-edge transition of progressive tumoral cells: a critical review on differential yet corroborative roles for HIF-1\u03b1 and HIF-2\u03b1","volume":"242","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0250","doi-asserted-by":"crossref","first-page":"117049","DOI":"10.1016\/j.lfs.2019.117049","article-title":"Stromal reprogramming: a target for tumor therapy","volume":"239","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0255","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/jcb.27703","article-title":"Cancer-associated fibroblasts: secretions, interactions, and therapy","volume":"120","author":"Farhood","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.clim.2021.108707_bb0260","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX\u2013bevacizumab drug treatment regimen","volume":"76","author":"Limagne","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cbin.11506","article-title":"Redox tolerance and metabolic reprogramming in solid tumors","volume":"45","author":"Mortezaee","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.clim.2021.108707_bb0270","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2021.108707_bb0275","first-page":"1","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.clim.2021.108707_bb0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0290","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189848","article-title":"Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O\u2019Neil","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2021.108707_bb0300","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0305","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/cas.14340","article-title":"Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: subgroup analysis from the KEYNOTE-100","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0310","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0315","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti\u2013PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0320","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"13","key":"10.1016\/j.clim.2021.108707_bb0325","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122092","article-title":"T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma","volume":"3","author":"Hopkins","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clim.2021.108707_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17414-y","article-title":"Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer","volume":"11","author":"Terranova-Barberio","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2021.108707_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000173","article-title":"Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2\u2212 negative endocrine-refractory metastatic breast cancer","volume":"8","author":"Shah","year":"2020","journal-title":"J. Immunotherapy Cancer"},{"key":"10.1016\/j.clim.2021.108707_bb0340","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.clim.2021.108707_bb0345","series-title":"The Efficacy and Safety of Combined Immune Checkpoint Inhibitors (Nivolumab plus Ipilimumab): A Systematic Review and Meta-Analysis","author":"Gu","year":"2020"},{"key":"10.1016\/j.clim.2021.108707_bb0350","article-title":"Comparative efficacy and safety of nivolumab and nivolumab plus ipilimumab in advanced cancer: a systematic review and meta-analysis","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clim.2021.108707_bb0355","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0360","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1634\/theoncologist.2019-0129","article-title":"Safety of Nivolumab plus low-dose Ipilimumab in previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"24","author":"Morse","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clim.2021.108707_bb0365","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Faculty of 1000 evaluation for durable clinical benefit with Nivolumab plus Ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0370","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e112","article-title":"A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D","volume":"30","author":"Lee","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0375","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2021.108707_bb0380","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clim.2021.108707_bb0385","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0390","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.03.013","article-title":"The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis","volume":"132","author":"Orhan","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.clim.2021.108707_bb0395","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2018.02028","article-title":"Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer","volume":"9","author":"Foulds","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108707_bb0400","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0405","first-page":"1","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0415","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-36129-1","article-title":"Analysis of expression of the PD-1\/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors","volume":"8","author":"Sampedro-N\u00fa\u00f1ez","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2021.108707_bb0425","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0430","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108707_bb0435","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","article-title":"Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced\/recurrent ovarian and uterine cancers","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0440","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13048-019-0512-6","article-title":"Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study","volume":"12","author":"Wang","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.clim.2021.108707_bb0445","article-title":"Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: a systematic review and meta-analysis","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.clim.2021.108707_bb0450","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clim.2021.108707_bb0455","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clim.2021.108707_bb0460","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0465","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0470","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2021.108707_bb0475","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0480","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12185-018-2509-0","article-title":"Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma","volume":"108","author":"Nakashima","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.clim.2021.108707_bb0485","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia\u2013lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0490","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0495","article-title":"CXCL12\/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis","volume":"117534","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0500","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0505","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1\u20133 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"key":"10.1016\/j.clim.2021.108707_bb0510","first-page":"1","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2021.108707_bb0515","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/cbin.11187","article-title":"Extracellular-signal-regulated kinase\/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review","volume":"43","author":"Najafi","year":"2019","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.clim.2021.108707_bb0520","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","article-title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","volume":"30","author":"Hellmann","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0525","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2021.108707_bb0530","doi-asserted-by":"crossref","first-page":"116520","DOI":"10.1016\/j.lfs.2019.05.076","article-title":"Cancer stem cell (a) symmetry & plasticity: tumorigenesis and therapy relevance","volume":"231","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2021.108707_bb0535","series-title":"Abstract CT075: Phase I Evaluation of M7824, a Bifunctional Fusion Protein Targeting TGF-\u03b2 and PD-L1, in Patients with Human Papillomavirus (HPV)-Associated Malignancies","author":"Strauss","year":"2019"},{"key":"10.1016\/j.clim.2021.108707_bb0540","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2021.108707_bb0545","first-page":"1","article-title":"Hepatotoxicity in patients with solid tumors treated with PD-1\/PD-L1 inhibitors alone, PD-1\/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis","author":"Guo","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2021.108707_bb0550","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2020.00261","article-title":"The risk ratio of immune-related colitis, hepatitis, and pancreatitis in patients with solid tumors caused by PD-1\/PD-L1 inhibitors: a systematic review and meta-analysis","volume":"10","author":"Tian","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clim.2021.108707_bb0555","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10120-019-00983-3","article-title":"Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance","volume":"23","author":"Pernot","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clim.2021.108707_bb0560","first-page":"674","article-title":"Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer","volume":"18","author":"Perrot-Applanat","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.clim.2021.108707_bb0565","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:03:08Z","timestamp":1761494588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661621000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":113,"alternative-id":["S1521661621000449"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108707","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108707"}}